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Psoriatic arthritis (PsA) is a complex heterogeneous disease with multiple inter-related
pathologies such as synovitis, enthesitis, tendinopathy, and dactylitis. Clinical
assessment is limited in its detail to assess pathology, thus in recent years, ultrasound
(US) has become more popular, given its high sensitivity to detect inflammatory arthritis
and ability to inform clinical decisions. Although a qualitative technique, US findings can
be graded semi-quantitatively for grayscale (GS) and power Doppler (PD). Synovitis is
frequently present in inflammatory arthritis pathologies, and in PsA, recent evidence
shows a propensity for tendon and entheseal lesions. The presence of flexor tenosynovitis
and flexor tendon insertional enthesopathy at accessory pulleys is supportive of the
“Deep Koebner” concept. Peri-tendinous inflammation—mutual to PsA or rheumatoid
arthritis (RA), is associated with soft tissue oedema with PD signal frequently at the
flexor tendon compartments in PsA. Research on enthesitis in PsA/PsO has improved
understanding in subclinical and clinical PsA, explored associations with progression
to PsA, and investigated links to prognosis assessment. Dactylitis is a pathognomonic
PsA lesion where US has enhanced knowledge of the disease course and pathology
of lesions such as: flexor tenosynovitis; synovitis; and soft tissue oedema. Increased
US sensitivity has also brought innovation including promising automated ultrasound
scanning techniques. So, what have we learnt in recent years and what are the unmet
needs to focus future research initiatives in this disabling disease? This narrative review
article assesses the neoteric evidence, bringing into context the knowledge gained and
highlighting potential areas of research.
Keywords: spondyloarthritis (including psoriatic arthritis), enthesitis, dactylitis, synovitis tendon inflammation,
peri-tendon inflammation, tenosynovitis, ultrasonography
INTRODUCTION
Psoriatic arthritis (PsA) is a heterogeneous disease characterized by joint, tendon, and entheseal
inflammation in both the peripheral and axial skeleton. At these sites, inflammation gives rise
to pain, tenderness and swelling which is either localized around a joint or more diffuse e.g.,
along a whole digit (dactylitis). Categorized as one of the main disorders under the umbrella
term Spondyloarthritis (SpA), PsA incorporates associated extra-articular manifestations including
cutaneous psoriasis (PsO), related onychodystrophy, inflammatory bowel disease and uveitis.
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The musculoskeletal burden is comparable to rheumatoid
arthritis (RA), with joint related damage, functional impairment
and reduced quality of life over time (1).
The challenges of diagnosis in early PsA are not confined to
the heterogeneity of disease, which is evident from the variety
of outcome measures available (2). In contrast to RA, there
are no biomarkers such as anti-citrullinated peptide antibody
(ACPA) or rheumatoid factor (RF) to identify early PsA and
therefore diagnosis is dependent upon identification of specific
clinical features. In addition, elevation of acute phase markers
such as C-reactive protein (CRP) only occurs in up to half of
patients and is therefore of limited value in early PsA (3). Lastly,
the absence of PsO in the presence of arthritis may lead to a
label of undifferentiated arthritis. Reflecting these shortcomings,
imaging has been increasingly utilized for PsA evaluation and
therapy assessment.
Plain film radiographs of joints are feasible, quick to perform
and low in cost, with the ability to assess progressive damage
reasonably well. However, when compared to ultrasound (US)
or magnetic resonance imaging (MRI), they lack sensitivity for
detecting early inflammatory arthritis and associated damage
(4, 5). Ultrasonography (US) has various advantages over MRI,
including greater accessibility, overall reduced cost, lack of
contraindications, and its availability in the clinic. However, MRI
has the advantage of allowing access to sites where US has a
limited acoustic window e.g., axial skeleton and all osseous based
pathology. Given the mounting evidence on early treatment of
active inflammation for optimal outcomes, the need for adopting
sensitive imaging tools into routine practice has never been
greater. The aim of this review was to evaluate the recent research
literature on US use in PsA with relevance to clinical practice.
METHODS
A panel of rheumatologists undertook this project. Although
no systematic search was performed as such, the Patient-
Intervention-Comparison-Outcome (PICO) standard was
adhered to. Intervention: the search strategy focused on
scientific publications reporting on the use of US for diagnosis,
management and assessment of PsA. Population: the target group
included adults (≥ 18 years of age) with a diagnosis of PsA of any
disease duration. Specific PsA musculoskeletal manifestations
explored were synovitis, dactylitis, and enthesitis. PsA-related
spondylitis was not included due to unfeasible accessibility of
axial skeleton structures to US imaging techniques. Comparator:
the imaging techniques appraised, whenever available, were
conventional radiography, computed tomography (CT), and
MRI. Outcome: no pre-set outcome measures were chosen,
as the panel felt that a restricted approach would narrow the
focus of the review excessively. Whenever available, measures
of diagnostic accuracy (sensitivity, specificity, positive/negative
predictive values, and likelihood ratios) were retrieved (Table 1).
The search strategy encompassed clinical trials, well-designed
cohorts and systematic reviews published in Pubmed from
2015 onwards and was performed by two members of the
working party (SRD, GDM). Only publications in English were
considered. Key papers before 2015 were included if considered
relevant to the review.
RESULTS
Ultrasound for Diagnosis
Synovitis
Grayscale (GS) US findings in PsA are similar to those of RA in
morphology with synovial hypertrophy, intra-articular effusion,
enhanced power Doppler (PD) signal, and erosions (Figure 1A).
However, the literature shows a trend to higher severity in
RA synovitis as compared to PsA (6, 7). In these studies
focussing on synovitis in PsA, US showed more prominent
tendinous/entheseal involvement adjacent to synovial joints
in the PsA groups (8, 9). Absence of PD signal over the
hypertrophic tissues, however, did not rule out active intra-
articular synovitis (6). Preliminary data suggested that the
pathologic processes in the intra-articular synovia may follow –
not precede- inflammation at the level of soft tissues surrounding
extensor tendons in the hands (9, 10). One limitation of US,
in the context of the evaluation of psoriatic polyarthritis, could
be the amount of time needed to perform such investigation,
as compared to clinical evaluation. However, automated US
scanning techniques showed 2-fold higher sensitivity in detecting
synovitis of the hands, when compared to clinical examination,
and have potential for improving the current standard of care in
rheumatology clinics (10).
Subclinical Synovitis: What Does it Mean?
Attribution of articular swelling to synovitis is better performed
by US as compared to clinical examination, especially at a
sub-clinical stage. Subclinical synovitis as detected by US is
frequent in subjects with psoriasis and healthy individuals (up
to 49.6% may show at least one abnormality, in at least one
site investigated). Although less common, PD signal suggestive
of subclinical synovitis was present in 24% of healthy subjects
(11). It is interesting to note that in the healthy subjects recruited
in this cross-sectional study, PD signal showed mild alteration
(grading 1 out of 3) and lesions scoring 2 or 3 were uncommon or
absent, respectively. Of note, PsA patients recruited in this study
had subclinical synovitis more frequently, affecting more sites
and with more severe PD signal alterations. Frequent findings
of subclinical synovitis in healthy subjects (55%) and psoriatic
patients (85%) were confirmed by another cross-sectional study
(12). However, in this report, “active synovitis” (that is, the
combination of synovial hypertrophy with PD signal) was
found exclusively in psoriatic subjects (27.5%) (12). Histological
evaluation would ideally be needed to disentangle the meaning of
these imaging findings in pre-clinical PsA and in normal.
Subclinical synovitis -with or without subclinical enthesitis-
at baseline is more frequent in psoriatic patients who develop
PsA over a follow-up of 2 years (13). In PsA patients who are in
clinical remission/minimal disease activity, US detection (using
associated PD) of non-clinically noticeable synovitis is a predictor
of short-term (6 months) flare (14).
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TABLE 1 | References appraised and selected for inclusion.
Ultrasound for diagnosis
• Synovitis
Records evaluated: 80;
Records included: 6 (2 relevant references from > 5 years included)
• Subclinical synovitis
Records evaluated: 65;
Records included 4
• Tendon pathologies
Records evaluated: 97;
Records included 10 (of which 2 are also cited in “synovitis”) (3 relevant references from > 5 years included)
• Entheseal pathology
Records evaluated: 126;
Records included 13 (of which 1 already cited in tendon pathologies) (1 relevant reference from > 5 years included)
• Dactylitis
Records evaluated: 38;
Records included 5 (0 references from > 5 years)
• US in differential diagnosis of PsA
Records evaluated: 134;
Records included 4 (of which 1 already cited in tendon)
• Limitations of US in clinical practice
Records evaluated: 43;
Records included 1 (0 references from > 5 years)
• Comparison of US with clinical examination and composite clinical scores
Records evaluated: 101;
Records included 5 (of which 1 is already cited in “dactylitis”); (1 relevant reference from > 5 years included).
Ultrasound for management
• US for management
Records evaluated: 59;
Records included: 2 (0 references from > 5 years)
• Monitoring of PsA
Records evaluated: 280;
Records included 2 (0 references from > 5 years)
• Remission assessment
Records evaluated: 120;
Records included 3 (of which 2 already cited in subclinical synovitis and comparison of US with clinical examination) (1 relevant reference from > 5 years included)
• Prognosis
Records evaluated: 87;
Records included 4 (of which 1 already cited in tendon)
• Composite US scores (joints, entheses)
Records evaluated: 19;
Records included 9 (of which 1 is also cited in “tendon pathologies”), (3 relevant references from > 5 years duration).
• Guided injections
Records evaluated: 116;
Records included 4 (2 relevant references from >5 years).
Tendon Pathologies
Tendinopathic pathologies can exist in both PsA and RA but can
be difficult to attribute specifically to either disease. Benjamin
et al. (15) described the concept of a “functional enthesis,” an
anatomical, biomechanical, and pathological feature that share
fibrocartilaginous entheses proximal to regions of attachment to
allow tendons or ligament to wrap around bony pulleys. It is at
these sites that there is a propensity for disease in PsA which
has been confirmed through US (16). Flexor tenosynovitis can
be detected by high-resolution US of the hand flexor tendons
as illustrated in Figure 1B. Peri-tendinous soft tissue oedema
and PD signal have been reported in the 2nd−4th flexor tendon
compartments of the dominant hand in one third of PsA vs.
no RA patients (8, 17). Additionally, flexor tendon insertional
enthesopathy occurs at accessory pulleys including new bone
formation, significantly more common in PsA, supporting the
“Deep Koebner” phenomenon (18). A much higher percentage
of peritendinous extensor digitorum tendon inflammation was
Frontiers in Medicine | www.frontiersin.org 3 August 2020 | Volume 7 | Article 487
Dubash et al. Ultrasound Imaging in Psoriatic Arthritis
observed in PsA compared to RA (9). Soft tissue oedema was
detected almost exclusively in PsA when the most clinically
involved finger was assessed. Further, central slip enthesitis at
the PIP joints was exclusively found in early PsA. Ultrasound
detection of extra-synovial features and at the synovio-entheseal
complex may be helpful in the differential diagnosis between
early RA and early PsA (9).
There is some expert based consensus that the most useful
anatomical sites for identifying disease at tendons (with sheaths)
are at the hand flexor tendons, extensor tendon compartment
of the wrist, and for peri-tendonitis (inflamed tendons without
sheath) hand extensor tendons are favored over the feet extensor
tendons (19).
Further recent studies have also added to the literature
on significantly greater tendon sheath synovial thickening and
tendon sheath PD signal observed in PsA compared to PsO
without PsA (20). On a practical level, a previous study
demonstrated greater peritendon extensor tendon inflammation
at the MCP level in PsA than RA, indicating that it is a key
characteristic of PsA, valuable in differential diagnosis (10).
Importantly in PsA, the most recent evidence indicates that
MCP swelling is actually attributable to not only synovitis, but
also peri-tendonitis (Figure 1A), and are detectable at similar
frequencies (21).
Entheseal Pathology
Enthesitis is considered characteristic of PsA and an early lesion
throughout disease progression (22). The clinical assessment of
the entheses can be impaired by lack of sensitivity and overlap
with pain amplification syndromes (23, 24). Moreover, data
suggest a disconnection between arthritis severity and enthesitis
severity (25). Although recent studies found no correlation
between the clinical and the US assessments of entheses in PsA
there is potential for increased accuracy of enthesitis assessment
using US scan (26, 27).
OMERACT proposed (28) a definition for the
elementary lesions that characterize enthesopathy: (1)
“hypoechogenicity at the enthesis”; (2) “thickened enthesis”;
(3) “calcification/enthesophyte at enthesis”; (4) “erosion at
enthesis”; (5) “Doppler signal at enthesis” (Figures 1C–E). Some
of these lesions are structural and commonly seen in people
not affected by PsA, although in PsA they tend to be more
severe (29–31). Moreover, the definition of PD alterations within
2mm from the enthesis is not accepted by the whole scientific
community. Furthermore, body weight and other mechanical
factors and metabolic conditions are considered confounders for
enthesopathic structural lesions (17, 32). However, US-detected
active enthesitis (that is, the combination of elementary lesions 1
and 5) is related to older age and higher levels of physical activity
in PsA patients (33). Interestingly, inflammatory entheseal
changes are commonly found in people who have psoriasis or
arthralgia and psoriasis, preceding the clinical onset of PsA. In
the study by Zabotti et al. (32) the presence of US evidence of
enthesitis was associated with progression to PsA.
Dactylitis
The use of US has added to the understanding of pathologies
involved in dactylitis that extend beyond the presence of synovitis
and flexor tenosynovitis. In a recent study of dactylitis in PsA
patients, joint synovitis was detected by US in 40% of dactylitic
digits and was associated with longer duration of dactylitis
and the asymptomatic “cold” type characterized by swelling
but not pain or tenderness (34). Another study of psoriatic
dactylitis identified PD at the accessory pulleys of affected digits,
suggesting that these sites of mechanical stress may be more
important in the disease process than previously thought (35).
Moreover, flexor tenosynovitis is most prevalent in the majority
of PsA imaged dactylitis and over half of patients also display
subcutaneous oedema and synovitis (36). Unlike the OMERACT
US definitions aforementioned for synovitis and enthesitis, no
widely accepted ultrasound definition was present for dactylitis.
Just recently, Zabotti et al. (37) have developed an US score
for dactylitis, namely the DACTylitis glObal Sonographic score
in PsA (DACTOS). Dactylitis elementary lesions were reviewed
via a Delphi exercise of 12 experts to reach a consensus on
scoring which resulted in moderate/excellent reliability for US
scored lesions (37). Imaging scores of such may assist in the
diagnosis and evaluation of the response of tissue compartments
to therapies (38).
US in Differential Diagnosis in PsA
The morphological similarities between PsA synovium and that
of RA leave open substantial issues related to the differential
diagnosis of inflammatory arthritides. Narrowing the view on
synovitis, the integration of contrast enhancement technique to
US scans may assist in distinguishing across different diseases.
Some evidence points to the potential of different software for
quantitative analysis of the kinetic parameters of the synovial
vascular perfusion pattern. In one study, this sophisticated
technique has shown discriminatory ability in the assessment of
RA vs. other forms of arthritis, including PsA (39). However, such
advanced analysis tool would be available only in research centers
for now.
Beyond synovitis, the available evidence supports the concept
that PsA is mainly differentiated from RA by the involvement of
non-synovial articular and peri-articular structures/tissues (17,
40). Key findings are enthesitis, peritendonitis of the extensor
tendons of the hands, thickening of the pulleys of the flexor
tendons of the hands, peri-tendineal dermal soft tissue oedema
and bone proliferation associated with erosions (usually smaller
than RA). The presence of extra-synovial features on US of
the hands showed sensitivity of 68% and specificity of 88.1%
for early PsA (16). Some limitations apply, since most studies
were performed on limited parts of the musculoskeletal system
(hands and wrists mainly). Moreover, the comparisons were
made between RA, seronegative SpA and PsA (leaving out
crystal-caused arthropathies, especially the chronic forms).
The Limitations of US in Clinical Practice
On a practical level, clinical examination, which is subjective
and not anatomically nor pathology specific, is complemented by
the high sensitivity of US to detect inflammatory and structural
lesions, clearly advantageous to identify characteristic PsA-
related pathologies. Despite these significant benefits, a recent
systematic review reported variable diagnostic accuracy for US
in PsA, in fact confirmation of a PsA diagnosis was heavily
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FIGURE 1 | Characteristic ultrasound appearances in Psoriatic arthritis. (A) Longitudinal view through a metacarpophalangeal joint with synovitis. There is gray scale
(Continued)
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FIGURE 1 | thickening (*between joint and extensor tendon-dotted line) and marked increased power Doppler signal (grade 3, right image) consistent with “active”
synovitis and peri-tendonitis (*above tendon). MC, metacarpal; P, phalanx. (B) Longitudinal view through the flexor tendon on a finger. It demonstrates fluid and
synovial thickening within the tendon sheath (*). There is also marked power Doppler signal within the tendon sheath (right image). MC, metacarpal; P, phalanx. (C)
Enthesitis of common extensor origin (CEO): Longitudinal view through the common extensor origin. Hypoechogenicity (arrow/left), loss of fibrillary pattern (*), Bone
spur (BS), increased Doppler signal (small arrows/right) within 2mm (dotted line) of bone surface. (D) Longitudinal view through the plantar fascia of a patient with
PsA. There is thickening of the fascia (dotted yellow line measuring 8.3mm; normal < 5mm). Power Doppler signal is rarely seen at the plantar fascia insertion. Bone
irregularity is suggestive of erosive change (arrows). (E) Longitudinal section through the proximal patellar tendon. The tendon is markedly thickened (dotted arrow),
hypoechogenic (compared to normal tendon more distally) and has lost its fibrillary pattern. The bone surface of the patella shows bone irregularity consistent with
erosive change (white arrows). This was confirmed on transverse view.
based on clinical diagnosis and classification criteria (CASPAR)
(41). One should also be cognizant that the objectivity of US
is dependent upon having a skilled operator for scanning and
image interpretation, and a sensitive US machine/ transducer,
particularly relevant for PD signal detection. Further, it is
unfeasible to scan 68 joints and numerous entheses for every
patient in routine clinical practice due to time constraints,
therefore comprehensive US assessments of this nature occur
mostly in a research setting. There are also costs to be considered
involving the purchase, running, and servicing of the equipment.
Comparison of US With Clinical
Examination and Composite Clinical
Scores
A recent study has confirmed that in fact there is a significant
association between clinical and US assessment of the large
entheses when assessing Achilles and Patellar tendon origins (42).
Furthermore, digital pain and tenderness in dactylitis was linked
to US tenosynovitis GS ≥ 2 (34). However, large discrepancies
have been reported between clinical examination and US findings
for synovitis and enthesitis (43). In the same study, the DAPSA
composite scores partially reflected Boolean’s remission criteria
and correlated with GS and PD synovitis but not the CPDAI
(43). In another longitudinal study of 47 PsA patients, the SJC66,
CRP, ESR, DAS28, and the physician global assessment were
associated with PD, whereas the DAPSA was not (44). Therefore,
the discordance between clinical examination and US synovitis
needs further research. However, a recent report on clinical low
disease activity (LDA) states, (determined by DAPSA, PASDAS,
CPDAI, or MDA) suggests they are able to differentiate between
high and low (MUDA) US determined disease activity (45).
The unmet needs and suggested areas to focus US research in
diagnosis and management of PsA are summarized in Table 2.
MANAGEMENT
Ultrasound for Management
The EULAR recommendations for the use of imaging in the
diagnosis and management of SpA in clinical practice suggest
that US has a place in providing “additional information” on
top of clinical examination and laboratory investigation for
monitoring the activity of peripheral SpA, including PsA (46).
Perhaps surprising is that in RA, recent data showed a dichotomy
between the relationship of the clinical TJC and SJC with US
synovitis suggesting TJC is not associated with US synovitis, but
data from similarly large cohorts for PsA is missing (47). The
complex relationship between clinical and US examination is
poorly understood in PsA and would suggest the inclusion of
US can aid the assessment of disease where clinical assessment
may have missed underlying occult PsA disease activity. As
well as for disease monitoring, remission status, and disease
activity measures, we evaluated data for the value of US in
prognostication and targeted therapeutic interventions (intra-
articular injections).
Monitoring of PsA
One study on PsA looking at the utility of US in the clinic
showed that PD signal detected at baseline was not associated
with response to treatment at 4 months [either biologic or
conventional synthetic disease-modifying anti-rheumatic drugs
(bDMARDs, csDMARDs, respectively)] in the routine care
setting (48). These findings contrast with those from studies in
RA, so Højgaard et al. (48) argued that one possible explanation
could be the different presentation of the two diseases (that is, RA
is more symmetric/uniform than PsA). The possibility remained
that PD signal grading continuum, notmerely its presence, would
be more relevant for prognosis. In the TICOPA imaging substudy
US inflammation scores were based on summation of GS and PD
and both these features were graded 0–3. In this underpowered
substudy, the US-based measure demonstrated responsiveness,
was aligned to clinical outcome measures at baseline, and was
aligned to the change detected by clinical outcome measures
between two different time-points (49).
Remission Assessment
In PsA patients who are in clinical remission/minimal
disease activity, US detection of subclinical synovitis
using PD was a predictor of short-term (6 months) PsA
flare (14). There is however, evidence of poor correlation
between levels of clinical PsA activity (as measured by
composite outcome measures) and US inflammatory
findings (above all, PD signal) (50). US remission was
found in 49.6% of the patients in this cross-sectional
study, while clinical remission was achieved by 5.7–9.9%
of the patients (depending on the composite outcome
measure used). In this study, patient-reported-outcome-
measures, a component of many clinical composite outcome
measure, correlated with US findings worse than swollen
joint count.
In another study, in 20% of PsA patients with clinically active
disease (as measured by clinical composite outcome measures
such as DAPSA, PASDAS, CPDAI, MDA) US assessment resulted
in minimal inflammatory activity (MUDA) (43). In this study,
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TABLE 2 | Unmet needs in ultrasound imaging in Psoriatic arthritis.
Topic of interest in PsA Unmet needs: suggested research focus, by clinical phenotype
Psoriatic oligo/polyarthritis Psoriatic dactylitis
Diagnosis:
Sensitivity and specificity: • PsA is frequently underdiagnosed or misdiagnosed. Can US
improve the PsA diagnostic yield?
• The specificity of US features to PsA is an area where further
knowledge may improve clinical diagnosis given that
overlapping pathologies exist between diseases.
• Larger sized prospective cohorts may provide further insight into
the characterisation of US features useful to differentiate
different inflammatory arthritides (e.g., RA, PsA/SpA,
crystal arthropathies).
• Dactylitis is a unique lesion in PsA. Yet the significance of dactylitis
is still unclear in terms of the overall burden of disease in PsA.
Further research on this lesion and US in PsA will drive further
knowledge and understanding of this pathognomonic lesion in
PsA/SpA.
• The nature of dactylitis from early disease onset into chronic PsA
is not fully understood. More research from large PsA cohorts
may explain this further.
• High sensitivity US may be useful in detection of small entheseal
tissue in dactylitis research.
Synovial
Synovitis:
• Disparity between clinical examination and US findings in PsA is
still not well-understood. The relationship between clinical
examination and US for identifying synovitis (and enthesitis
below) is poorly understood and requires further research to
clarify and inform clinical practice and decision making.
• The large number of joints in the Psoriatic joint clinical/US
assessment is time limiting and impractical in the clinic. A
condensed, time-sensitive, but valid and reliable US tool that
can be easily implementable is required for practicality in clinical
practice and research.
• More work on longitudinal PsA/PsO cohorts needed on the
subject of subclinical synovitis and its prognostic value in the
short and medium term (up to 5 years of follow-up).
• What is the relationship between dactylitis and synovitis? Does
this differ depending upon disease course or treatment type?
• Are there any ultrasound predictors that determine why some
people with dactylitis may be affected by worse outcomes?
• PsA cohorts with dactylitis may provide more insight into future
dactylitis research.
• Is there a risk from dactylitis to overall disease related affliction
and treatment in early disease?
• Does synovitis represent risk of dactylitis relapse/recurrence?
Extra-synovial
Enthesitis:
• Discordance between clinical an US enthesitis suggests further
studies may inform the differentiation between PsA and
non-PsA.
• Is an enthesitis US composite research score needed? If so,
how many entheses should be included and which ones?
• The enthesis organ concept is highly implicated in PsA, yet we do
not know whether dactylitis results in more clinical/US enthesitis?
• Does dactylitis represent an intermediary lesion in the disease
spectrum, developing from enthesitis and next into synovitis, or
could it be a more significant clinical marker of disease severity
in early PsA? These are questions that future US research may
be able to answer using US at time-points in PsA evolution.
Tendon related
pathologies:
• Research to improve differentiation of tendon pathologies in
early PsA from RA or Palindromic rheumatism is where US may
inform clinical practice.
• Further research is needed on imaging of tendon pulleys and
sheaths in early PsA which may hold early diagnostic value.
• Identification of flexor/extensor tendons, peritendinous regions:
where, when, and which should we scan? Is there a significance
in terms of the disease overall burden?
• Tendon pathologies are key pathological features in dactylitis and
correspond to the anatomical concept of swelling across the
whole digit. Further understanding of tendinopathy in this lesion
may improve targeted PsA therapy per patient based upon lesion.
• Flexor tenosynovitis and flexor tendon sheath and pulley
pathologies are key components of dactylitis.
• Peritendon inflammation: US vs. MRI, disease course and
response to therapy.
• Scoring is a “hot” topic: Validation of scoring methods can permit
use in research and clinical settings.
• Hot and cold differentiation and active pathologies: clinical
examination findings could be included to encompass the best
representation of dactylitis status.
Management:
US disease activity
scores/composite outcome
measures for monitoring
• How should overall US disease activity be measured per
patient?
• Which composite measure should be used?
• Isolated US vs. combined clinical and US features of dactylitis
should be considered to assess dactylitis disease activity and
monitor treatment response.
• Clinical trials and longitudinal cohort studies may provide further
clues into this arena where the data is sparse.
Disease remission: • Clinical vs. US remission: which should be used? How should US remission/low disease activity be defined? More research in this
area is needed.
Pragmatic, additional
issues:
• Advancing technologies are emerging which allow automated and simplified assessment of joints in less time. Can they be reliably
and validly implemented and with cost-effectiveness?
the pain-related items, as part of the clinical composite
outcome measures, were the components conditioning
higher disease activity scores. The authors postulated that
the evaluation of clinical treatment targets can benefit from
US evaluation.
Prognosis
In PsA patients clinically classified as oligoarthritis, US scanning
has uncovered synovial hypertrophy of polyarticular distribution
(51). Similar findings are relevant for the assessment of PsA
prognosis. Baseline US findings of synovitis (upon GS and
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PD assessment) were identified as risk factors for additional
articular damage in one study (52). In this study, the presence of
baseline enthesopathy/enthesitis also accounted as a risk factor
for articular damage.
Another study found that 26 PsA patients who were in
clinical remission had low levels of PD signal on US scan.
Once csDMARD or bDMARD therapy was stopped the clinical
recurrence rate of PsA was high (90%). One predictor of PsA
relapse was synovial hypertrophy on US scan at the time
of therapy cessation (53). Further data on the assessment of
remission and prognosis are expected from the UPSTREAM
study (19).
Composite US Scores
Just as there are several clinical composite scores for the
assessment of PsA, US disease activity may be scored using a
number of validated methods for the joints and entheses in
clinical and research practice.
Joints
Two composite scores have been specifically developed to
monitor disease activity in PsA: the 5TPD and PsA-Son
composite scores with good sensitivity to detect inflammation
and feasibility, but not yet validated in any other series (19).
Following the suit of many rheumatology clinical composite
scores, Ficjan et al. (54) proposed two US scoring methods
to assess inflammatory and structural PsA lesions, the PsA-
Son13, (unilateral joints), and PsA-Son22 score (bilateral joints).
They reported sufficient construct validity, reliability, and
sensitivity to change for both scores. The reduced number
of joints included may be considerably time saving, however
there is potential to miss involved joints leading to a false
reflection of overall disease activity, especially relevant for
oligo/monoarticular phenotypes.
The “5 targets Power Doppler for Psoriatic disease” (5TDP)
was based on joints, tendons, entheses, skin and nails scoring
the highest expression of PD signal (55). The limitations were
that the score does not consider multiple joint involvement from
single joint involvement and may lead to under estimation of
disease activity in polyarticular disease (55). A further drawback
is that nail and skinUS assessment is not commonplace in routine
practice and therefore not practical outside of a research setting.
Finally, it is notable that large joint involvement is frequent in
PsA, therefore a tool initially developed for validation in RA,
SOnography in LArge joints in Rheumatology (SOLAR), has
been reported for its suitability for PsA (56).
Entheses
In a recent study, the Madrid Sonographic Enthesitis Index
(MASEI), a scoring tool designed for enthesitis in SpA/PsA, failed
to distinguish between enthesitis in PsA from healthy controls
(57). It was found that by excluding the knee enthesis thickness
and refining PD severity, marked differences could be shown
between PsA patients and healthy controls, indicating that given
considerable overlap of features exists between groups, setting
the best discriminative thresholds for detecting pathology is
imperative (57). On the contrary, a recent systematic literature
review concluded that the MASEI was feasible, reliable and
a valid ultrasound score for assessing enthesitis, but did not
find any articles assessing MASEI as an outcome for treatment
response (58). Whether clinical tenderness is derived from
enthesitis or fibromyalgia can be difficult to assess, but has
recently been studied using US and scored via the Glasgow
enthesitis scoring system (GUESS) (59). It was found that US
enthesitis was more prevalent in PsA and PsA with fibromyalgia
compared to fibromyalgia alone, and clinical entheseal scores
(LEI, MASES) were shown to potentially overestimate active
enthesitis in fibromyalgia (59). A further preliminary enthesitis
score developed in a recent GRAPPA study has reported the
ability to differentiate between PsA and healthy controls (60).
However, this has led to further discussion/debate on whether
a further enthesitis score is actually needed, and if so, how
many entheses should be included, and the suggestion that
a study to prioritize differentiation of PsA from PsO and
osteoarthritis/mechanical pain should be prioritized (61).
Guided Interventions (Injections)
Ultrasound provides the ability to visualize the needle for
injection procedures and therefore optimize placement accuracy.
There are no specific recent studies on PsA and the effectiveness
of US guided routine intra-articular injections. However,
previous randomized controlled trials (RCT) in inflammatory
arthritis reported significantly better accuracy of joint injection
by US over the blind/palpation approach (62). In the same
study, the benefit of short-term outcomes could not be
demonstrated. Another larger RCT of 244 patients reported
superior outcomes and cost-effectiveness with US guided
injection vs. the conventional blind/palpation technique, with
an 81% reduction in injection pain, 35% reduction in pain
scores and 38% increase in responder rate (63). In contrast,
a large randomized trial examining the benefit of US in a
clinical tight control regimen in RA (ARCTIC) did not find any
significant difference in treatment efficacy between US guided
and blind/palpation guided joint injections (64). There is a clear
advantage of targeting pathologically active disease through US
assessment prior to US guided injection given that treatment
efficacy was observed when moderate PD synovitis was present,
independent of whether the joint was clinically swollen (64).
Given the multiple pathologies in PsA, it would seem reasonable
to study targeted US injections based on region and type of
pathology. Further research may clarify whether US guided joint
injection for routine intra-articular joint injections can produce
superior outcomes over routine blind approach, but the most
recent data is limited (6).
CONCLUSIONS
Ultrasound is complementary to clinical examination by adding
sensitivity and specificity to sites of disease in PsA enhancing
the qualitative assessment. Several recent studies have shown
added value of US in research by improving the understanding
of disease. The clinical role of US for diagnosis is ever more
assuring, yet there is discordance between clinical and US
assessment that needs further research. Composite scoring
measures remain research driven tools and are unlikely to be
implemented in busy routine clinics in the near future. As US
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becomes more widely used, its function as a disease monitoring
tool is promising, but further research is required to clarify its
specific role in the clinic.
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